Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Artificial intelligence (AI) deep learning is rapidly transforming the biotechnology and pharmaceutical industries. New AI models based on ChatGPT-like algorithms are emerging in many industry ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...
Cancer treatment has long been haunted by the same problem: how do you strike dangerous cells without hitting healthy ones ...
An international team involving the Institute of Chemical Research, a joint centre of the University of Seville and the Spanish National Research Council, has developed a new technique that will ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Morning Overview on MSN
DNA-based system targets cancer cells and releases drugs at tumors
Researchers at the Université de Genève have built a DNA-based drug delivery system that reads pairs of protein markers on a ...
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results